Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spilled Blood: CSL & Talecris Terminate Their Merger Deal In Face of FTC Lawsuit

This article was originally published in The Pink Sheet Daily

Executive Summary

The companies decide it is not worth the cost and time to battle the FTC in court; the derailed deal may signal tougher times for pharma mergers.

You may also be interested in...



Grifols To Divest Factor VIII Product Koate To Merge With Talecris

Italian company Kedrion will get the Factor VIII product Koate and a fractionation facility in Melville, N.Y., under a consent agreement with the Federal Trade Commission.

Grifols To Divest Factor VIII Product Koate To Merge With Talecris

Italian company Kedrion will get the Factor VIII product Koate and a fractionation facility in Melville, N.Y., under a consent agreement with the Federal Trade Commission.

FTC Taking A Closer Look At Talecris/Grifols Merger; HIGPA Voices Concerns

The Federal Trade Commission has requested further information from both Talecris Biotherapeutics and Grifols in relation to the two companies' proposed merger

Related Content

Topics

UsernamePublicRestriction

Register

PS069662

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel